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CHAPTER I 
INTRODUCTION 
Candida albicans (Robin) Berkhout is a moniliaceons fungus of the 
subfamily Cryptococcoideas, which can exist as a budding yeast-like 
cell (blastospore) or a branched pseudomycelium with whorled blasto-
spores and terminal chlançrdospores. Under "normal" conditions, the 
organism exists as a saprophyte on the skin and raucous membranes of 
man. Ç. albicans can, however, under certain conditions, become 
mycelial in the host and assume the role of a pathogaa. 
"Bie recognized pathogenicity of £. albicans dates back to the mid-
nineteenth century at which time it was reported to be implicated in 
oral thrush (Langerbeck, 1839) and vaginitis (Wilkinson, 18̂ 9)' 
Since the early 19U0's, clinical candidal infections have been 
reported on the increase (Kashkin et al̂ ., 1961) and systemic candidosis 
has become a recognized diagnostic and therapeutic problem (Wolfe and 
Henderson, 19̂ 1; Pearl and Sidransky, I960; Hyun and Collier, I960; 
Kay et al., 1961). Prom 19U0 until April, 1966, there were hi reported 
cases of candidal endocarditis with only five reported survivals among 
them (Utz, 1966). Although candidal infection of the brain, heart, 
lung, and other deep structures is not common, it is important because 
the infection is usually associated with a fatal outcome, 
Ihe increase in candidal infections may in part be attributed to 
the development of more accurate diagnostic techniques for the detec­
tion and identification of the organism (Rosenthal and Rimari, 1958; 
1 
2 
Taschdjian e;t al., I960; Walker et al̂ ., I960), However, since 19&0 
antibiotics used in the treatment of bacterial infections and corti­
costeroids used in correcting metabolic disturbances have been shown 
to predispose an individual to a superimposed fungal infection (Kashkin 
et al., 1961; Woods et al., 19l?l; Young et al., 1956). 
The mechanism of antibiotic predisposition of mucous membranes 
has been attributed to an inhibition of the normal bacterial flora 
(which normally maintains low numbers of £. albicans by competition, 
antibiosis, etc.) with a subsequent proliferation and invasion of the 
mucosa by G. albicans (Gorczca and McCarty, 19̂ 9; Isenberg et al., 
I960; Young et al., 19̂ 6; Pain, 1958). 
In the case of the corticosteroids, the mechanism of predisposi­
tion has been attributed to their effect on the reticuloendothelial 
system resulting in decrease in antibody production, in the inflamatory 
response process, and in phagocytosis (Kass et al., 1955; Germuth and 
Ottinger, 1950; Crepea et_â ., 1951; Bĵ rneboe et ̂ ., 1951; Michael 
and Whorten, 1951). Corticosteroids may also affect nonspecific re­
sistance (Seelig, 1966). 
Certain disease processes and metabolic disorders which directly 
or indirectly decrease host resistance may predispose an individual to 
candidosis. A positive correlation of abnormalities of leukocyte 
metabolism with impaired phagocytic capacity has been demonstrated in 
cases ôf diabetes, leukemia, and corticosteroid therapy (Seelig, 1966). 
Hie pathogenicity of C. albicans has been attributed to its abil­
ity to invade tissues in the mycelial form (Young, 1958) and to the 
production of toxic metabolites including an endotoxin (Salvin, 1952). 
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%e production of chlaraydospores by G. albicans has also been associated 
with the pathogenicity of the organism in endocarditis (Heineman et al., 
1961). 
There have been a great many agents employed in the treatment of 
superficial candidal infections: undecylenic acid (Kendall, 19h7), 
various fatty acids (Van Assen, 19̂ 0), caprylic acid (Lapan, 1959)» 
gentian violet (Hesseltine, 19̂ 5)» candicidin (Fox, 19̂ 5), nystatin 
(Jennison and Llywelyn-Jones, 19̂ 7), and sodium caprylate (Watt et al., 
1962). Some of these agents have been more successful and aesthetic­
ally more acceptable than others. However, there were two major 
problems which plagued the therapeutic use of the early antifungal 
agents in cases of systemic candidosis: 
a. the antifungal agent produced serious side effects in the 
host; 
b. the antifungal agent was toxic to the host in the concentra­
tion needed to exert its fungistatic or fungicidal effects on 
the fungus. 
It was not until the discovery of the polyene antibiotics in 19U9 
(Hazen and Brown, 19̂ 0) and more specifically amphotericin B in 19̂ 6 
(Gold et al., 19?6) that there appeared an effective agent for the 
treatment of systemic candidosis with a minimal incidence of serious 
side effects in the afflicted host. 
Amphotericin B was isolated from Streptomyces nodosus, idiich was 
recovered from a soil sample in the area of the Orinoco River in Vene­
zuela (Gold et al., 19̂ 6). ïhe antibiotic was characterized physically 
and chemically in 195& (Vandeputte et al., 19̂ 6; Donovick et al., 19̂ 6). 
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The mode of action of amphotericin B has been attributed to its 
ability to bind to the cell wall and cell membrane which subsequently 
results in an alteration in cell membrane permeability. Accompanying 
this alteration in cell membrane permeability is a loss of anions, 
cations and acids of the citric acid cycle. Terminally, cell respira­
tion and glycolysis cease (Marini e;t al., 1961; Kinsky, I96I5 Gale, 
I960). 
The primary problem which had to be overcome in order for ampho­
tericin B to be used therapeutically was its insolubility in water. 
Riis problem was overcome without loss of fungicidal activity by com-
plexing amphotericin B with sodium desoxycholate (Louria, 19̂ 8j Bartner 
et al., 19̂ 8). 
Amphotericin B has been used successfully in the therapeutic 
treatment of candidal endocarditis (Prinsloo and Pretorius, 1966; 
Kroetz et al., 1962), meningitis (Parillo et al., 1962) and septicemia 
(Sweeney and Dineen, I960; Louria and Dine en, I960). However, in some 
cases where a concentration of the antibiotic which inhibited growth 
of 2» albicans in vitro was reached, it appeared to be ineffective in 
combating the ssrstemic candidal infection (Kay et al., 1961). 
Concentrations of amphotericin B given intravenously in excess of 
1.Ç mg/kg generally produce serious side effects which may adversely 
affect the outcome of the treated infection. 
Hie present research problem is addressed in part to the questions 
Has Candida albicans resistance to concentrations of amphotericin B 
which would be toxic in a systemic human infection? 
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Iiones and Peacock (19̂ 9), Sorenson et al, (19?9), Littman et al, 
(I9̂ 8a), Lepper et al. (1959), Seabary and Dascotnb (1958), Hebeka and 
Solotorovsky (1965) and Utz et al̂ . (1959) have investigated the inhibi­
tory effects of amphotericin B on £. albicans» The concentrations 
which were reported to be fungistatic ranged from 0.2 to 3.7 /ig/ml 
(Seabury and Dascomb, 1958; Littman et al.. 1958a). Such wide varia­
tion may have been expected since most of the reports cited differed 
in the assay medium used for the determination of the minimal inhibitory 
concentration, the number of organisms used in the assay, the time after 
which the inoculated assay tubes were read, the method used to determine 
the per cent of inhibition of amphotericin B on £. albicans and the 
defined inhibitory point measured. 
Littman was the only investigator of those cited who reported a 
fungicidal dose of amphotericin B for a strain of G. albicans. This 
observation formed the basis for the second part of the research problems 
the determination of the fungicidal concentration of amphotericin B for 
6 clinical isolates of £, albicans. 
In the selection of naturally occurring resistant mutants to 
amphotericin B, Lones and Peacock (1959) reported that 12 strains of 
Ĝ . albicans grown for 52 serial transfers in culture media containing 
graded concentrations of amphotericin B all experienced an increase in 
tolerance to the antifungal agent. Accompanying this increase in toler­
ance to amphotericin B was a depressed growth rate among the derived 
strains and a decreased ability to form mycelium and chlamydospores on 
com meal and rice-polysorbate 80 medium. This observation formed the 
basis for a third area of research to be considered in this investigations 
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Does tolerance to amphotericin B result in a decrease in the ability 
of £. albicans to produce the characteristics associated with the 
pathogenicity of the parent strain, i.e., yeast-mycelium transformation 
and chlamydospore production? 
Finally, the author wished to determine the effect of amphotericin 
B on an immunologically depressed host and to determine if there is any 
correlation between immunological depressed, and the outcome of the 
amphotericin B-treated systemic candidal infection. 
CHAPTER II 
STATEMENT OF PROBLEM 
Candida albicans is a moniliaceous fungus which may assume the 
role of a systemic pathogen. This study was undertaken (l) to investi­
gate the fungistatic and fungicidal properties of amphotericin B on 
C. albicans; (2) to determine if characteristics associated with the 
pathogenicity of £. albicans are affected by exposure of £. albicans 
to fungistatic amounts of amphotericin B, and (3) to determine if a 
decreased host resistance affects the outcome of an amphotericin B-
treated candidal infection. 
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CHAPTER III 
METHODS AND MATERIALS 
Organisms Bnployed 
Six strains of Candida albicans which were isolated from clinical 
cases of vaginitis were employed in this investigation. %e 
strains were designated IB, 2A, 3A, ̂ A, 60, and 7A, respectively. 
Isolation of the Organism 
Primary isolation of the clinical isolates was made on Pagano-
Levine medium (Pagano et al., 19̂ 8). Colonies which appeared 
creamy-white or faintly pink in color (Gillespie et al., I960) 
were transferred to Sabouraud dextrose broth and then restreaked 
for isolation on Pagano-Levine medium. 
Identification of the Isolates as Candida albicans 
Bïe identification of the isolates as Candida albicans was based 
on the appearance of the organisms on Sabouraud agar, blood agar, 
and com meal agar with \% TVeen 80 (Walker et , I960). The 
ability of the organisms to produce germ tubes in human serum 
within h hours (Taschdjian ê  al., I960) and agglutinate in G. 
albicans antiserum (Rosenthal and Pamari, 1958) were also con­
sidered as criteria for the establishment of the identity of each 
isolate. If an isolate appeared as a white opaque budding yeast 
on Sabouraud and blood agar within U8 hours, produced a pseudo-
nycelium with whorled blastospores and terminal chlamydospores on 
8 
9 
com meal agar with 1% T»een 80, produced germ tubes in human 
serum within ii hours and agglutinated in £. albicans antiserum, 
the isolate was identified as £. albicans » 
(U) Culture Media 
Stock cultures of £, albicans were grown and maintained on modi­
fied Sabouraud agar (2% glucose, \% peptone, 1.?̂  agar) which was 
buffered to pH 7 with 2N NaOH. After incubation of the inoculated 
Sabouraud slants at 37°G for I4.8 hours, they were refrigerated at 
and a duplicate frozen at -80°G. The refrigerated stock cul­
tures were transfered monthly and periodically checked for contam­
ination microscopically and by streaking on blood agar. 
Modified Sabouraud agar made up in .001 M potassium phosphate 
buffer to pH 6.7 was used as the medium for all viable cell 
counts. 
Com meal agar with \% Tween BO was prepared by adding 17 gm of 
(Difco) com meal agar to 990 ml of distilled water. Hie medium 
was then heated until all components were completely dissolved. 
Before autoclaving the medium, 10 ml of Tween 80 were added to 
the flask. 
Modified Sabouraud broth which was made up in 0.001 M potassium 
phosphate buffer to pH 6.7 was used as an assay medium. 
Trjrpticase soy broth was prepared according to the BEL Manual 
(Baltimore Biological Laboratory, Inc., Baltimore, Maryland, 19̂ 6). 
Blood agar was prepared by adding SO ml of sterile human blood 
aseptically to a liter of trypticase soy agar which, after having 
been autoclaved was cooled to $0°C in a water bath. %e mixture 
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was swirled to obtain a uniform distribution of the blood and 
then dispensed into sterile petri plates and allowed to solidify. 
Pagano-Levine agar was prepared according to the Difco Literature 
Supplement (196U). 
Human plasma was obtained by centrifugation and filter-steriliza­
tion of outdated unhemolyzed human blood obtained from the blood 
bank of Saint Patrick Hospital, Missoula, Montana. 
(5) Chemicals 
Hydrocortisone acetate was obtained as a sterile suspension from 
Towne, Paulsen and Company, Inc., Monrovia, California. The 
suspension which contained 2̂  mg/ral was used undiluted directly 
from the vial as recommended by the pharmaceutical company. 
Amphotericin B* was obtained as a sterile lyophilized powder from 
E. R, Squibb and Sons, New York. Each vial contained $0 mg of 
amphotericin B which was coraplexed with sodium desoxycholate 
(Bartner ê â ., 19̂ 8). "Rie amphotericin B was refrigerated and 
reconstituted with sterile distilled water just prior to use. 
The hydrated unused amphotericin B was stored at $°C for no longer 
than one week or frozen at -20°C and kept for no longer than three 
weeks. 
Neomycin sulfate and triphenyl tetrazolium chloride were obtained 
in powder foiro from Nutritional Biochemical Corporation. 
* The trade name of E, R. Squibb and Sons for amphotericin B 
Fungizone. 
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Mice 
Mice used in this investigation were male adult white mice of the 
HML strain obtained from the Rocky Mountain Laboratory, U.S.P.H.S,, 
Hamilton, Montana. Ihe average weight of the mice used in the 
investigation was 28,? gm. 
Cîounting Method 
Five 1:10 serial saline dilutions were made of a cell suspension 
standardized to 60$ transmittance at a wave length of 660 mu. 
One-tenth ml aliquots of the standardized suspension were pipetted 
in duplicate from each dilution on to modified Sabouraud agar. 
The inoculum was uniformly spread over ttie surface of the agar 
with a sterile bent glass rod (hockey stick), Ihe plates were 
inverted and incubated at 37°G for 1̂ 8 hours. After incubation, 
colonies were counted with the aid of a Coulter colony counter 
and the number of organisms per ml calculated. 
CHAPTER IV 
EXPERIMENTAL PROCEDURES AHD RESULTS 
Bicperlment 1. Determination of the fanglstatic and fungicidal dose of 
amphotericin B for six strains of £. albicans. 
Forty-eight hours prior to the start of the investigative procedure, 
each of the 6 strains of £. albicans was inoculated on modified Sabour-
aud agar and incubated at 37°C, 
Screw-capped tubes, 16 x 1̂ 0 mm, were filled with 8.5 ml of modi­
fied Sabouraud broth. Ihe tubes were autoclaved at 1̂  psi for 1$ 
minutes, and then refrigerated until just prior to use. 
Immediately before use, 1 ml volumes of the desired concentration 
of the amphotericin B were added to the test tube series bringing the 
total volume before inoculation of the test strain of G. albicans to 
9.5 ml. 
Efeich strain of jC. albicans was washed from a U8-hour slant culture 
with physiological saline (0.85# NaCl). Each washed cell suspension 
was placed in a calibrated 16 x 150 mm screw-capped tube and inserted 
into a Coleman Model 6A spectrophotometer. The cell suspension was 
adjusted to 60% transmittance at a wave length of 660 ma. After adjust­
ment of the cell suspension, 0.5 ml was used as inoculum. Each series 
was run in duplicate. 
Viable cell counts of the standardized cell suspensions were made 
on modified Sabouraud agar. 
The optical density of all tubes was recorded at time zero and 
12 
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.1 .2 .3 .4 .5 
AMPHOTERICIN B CONCENTRATION, ug/ml 
Flexure 1. Inhibitor" qctivit ' of difff>r"nt concentrations of 
â mhotprlcln B on the < isolâtof £. albicans. The isolst̂ s 
reprpspntpd qbovn T'prp deri^n^ted as follovs: li A ; 6C ——; 
IB —2A • • 71 m ; "t.A. , 
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Table I, Effects of amphotericin B on growth of 6 isolates of Candida 
albicans in modified Sabonraud broth. 
Concentration of Isolates examined 
Amphotericin B ' 
(jigM) IB 2A 3A $A 60 7A 
0.1 65.7* 38,6 6I1.5 22.6 83.3 87.2 
0,2 10.9 22.6 12.6 6.3 gb.7 li3.2 
0.3 3.1 8.3 3.2 7.9 8.3 18.2 
0,h li.O 0.9 0.0 0.0 1.0 2,2 
0.5 0.2 0.0 0.0 0.0 0.0 0,0 
* O.D, experimental/O.D. control. 
again in U8 hears. After U8 hours, samples from each tube were streaked 
onto blood agar which was then incubated at 37°C for ̂ 8 hours. Yeast 
phase cells from positive blood agar plates were inoculated into human 
serum, incubated at 37°G for k hours and than checked microscopically 
for the production of germ tubes. 
The results of this investigation appear in Figure 1 and Tables 1 
and 2. Concentrations of amphotericin B ranging from 0.1 to Q.$ fig/ml 
affected the growth of the 6 strains of C. albicans to different de­
grees; however, all 6 strains were inhibited by 0.5 ;ig/ral of ampho­
tericin B. 
With the method cited above and the concentrations of amphotericin 
B employed, a fungicidal concentration of amphotericin B could be 
demonstrated for only one of the 6 strains of G. albicans « 
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Table II. Effects of amphotericin B on viability of Candida albicans 
in modified Sabouraud broth, li8 hr,, 37®C. 
Concentration of 
Amphotericin B 
()ig/ml) 
Isolates examined 
IB 2A 3A 60 7A 
0.1 +* + + + + + 
0.2 + + + + + + 
0.3 + + + + + 
O.ii + + + + 
0.5 + + + + + 
1.0 - 4- + + - + 
1.5 + + + + 4" -
2.0 + + + + + + 
3.0 + + + + + 
5.0 + + 
10.0** + + + •f - + 
20.0 + + + + - + 
30.0 + + + - + 
Uo.o + + - + 
50.0 + + + -
* + « viable organisms recovered on subculturej - • no viable 
organisms recovered, 
** Precipitates which appeared to be amphotericin B were noted 
at concentrations greater than 10 fig/ml. 
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Bcperlment 2. Determination of the effect of amphotericin B on G. 
alblcails loci different assay media. 
Sabouraud broth was modified so that the assay broths contained 
2% glucose, 1% peptone; 2% glucose, 0.1% peptone; 0,̂ % glucose, 0.1# 
peptone; and 0,̂ % glucose, 1% peptone, respectively. Except for the 
composition of the assay broth, the investigative procedure was the 
same as previously outlined (Experiment l). %e results of this exper­
iment appear in Figure 2. 
When the concentration of peptone was varied in the assay system, 
a marked decrease In growth of £. albicans was noted In the low-peptone 
media. This marked decrease in growth was present in both the anti-
blotlc-free and antibiotic-containing media. Varying the concentration 
of glucose, however, did not appear to affect the growth of G. albicans 
In either medium significantly. 
Experiment 3. Effect of human plasma and amphotericin B on U strains 
of G. albicans. 
Outdated human blood was obtained from St. Patrick Hospital. The 
plasma was drawn off the sedlmented cells, centrlfaged and then fllter-
sterlllzed. After filtration, 3»h ml of sterile plasma was pipetted 
into a series of 16 x 12$ mm screw-capped tubes and then refrigerated 
until just prior to use. At the start of ttie Investigative procedure, 
O.U ml of amphotericin B and 0.2 ml of a standardized cell suspension 
of G. albicans were added to the test system. All test cell suspensions 
were checked to determine if the organism was in the yeast phase. After 
the Inoculated assay cultures had been incubating for 1*8 hours at 37°C, 
17 
2% Glucose, 1% Peptone 
2% Glucose, 0.1% Peptone 
0.5% Glucose, 1% Peptone 
0.5% Glucose, 0.1% Peptone 
05 
AMPHOTERICIN B CONCENTRATION, pg/m\ 
PlfturR 2. Effects of peptone and glucose concentrations on the 
r̂oKth of C. albicans and the growth-inhibitory effects of amphotericin 
B. 
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slides were prepared from each assay tube and examined for the produc­
tion of germ tubes from the initial yeast phase culture. The presence 
of germ tubes in the assay cultures was inteirpreted to mean cell growth 
in the presence of the cited concentration of amphotericin B, One ml 
samples were also removed from each tube in the series and transfered 
to a blood agar plate and Erlenmeyer flask containing 12$ ml of sterile 
trypticase soy broth. The suspensions were spread over the surface of 
the blood agar plates with sterile bent glass rods. "Rie blood plates 
and trypticase soy broth flasks were incubated for U8 hours at 37°C 
and than read for growth. Of the organisms recovered after exposure 
to various concentrations of amphotericin B, representative colonies 
were checked for their ability to form germ tubes in human serum within 
U hours, %e results of this study appear in Tables III and 17 and 
Figure 3. 
"Hie fungistatic concentration of amphotericin B in plasma was 
observed to be greater than in broth. However, viability of the organ­
ism was lost much more rapidly in plasma than in the modified Sabouraud 
broth system. 
Figure 3. Effect of amphotericin B on C. albicans in human plasma: 
(A) Control lacking amphotericin B 
(B) 0.5 fxg amphotericin B/ml 
(G) 2,0 |lg amphotericin B/ml 
19 
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Table III, Effects of amphotericin B on growth of Candida albicans in 
huTBan plasma &8 hr., 37°C. 
Concentration of Isolates examined 
Amphotericin B " ' 
(pg/tnl) IB 2A 3A 6C 
0.0 ++++# ++++ ++++ ++++ 
0.5 ++ ++ ++ 4-+ 
1.0 + + + + 
2 #0 
3,0 - - - -
1&#0 — — — • 
#̂0 — — — — 
* Degree or extent of filaméntation was rated from extensive (++++) 
to none (-). 
Table 17. Effects of amphotericin B on viability of Candida albicans 
in human plasma, U8 hr,, 37°C, 
Concentration of Isolates examined 
Amphotericin B 
(pg/ml) 
IB 2A 3A 60 
BAP* TSB BAP TSB BAP TSB BAP TSB 
0,0 + + 
0,5 + + 
1,0 + + + 
2,0 + + + + + + + + 
3.0 + + + + + + 
U.o - + - + - + + 
5.0 - + - + - + 
* BAP • blood agar plates; TSB • trypticase soy broth, 
•** + • growth in subcultures; - • no growth in subcultures; + • 
both viable and non-viable cultures among replicates. 
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Experiment U. Determination of the effect of amphotericin B on m&ôelial 
formation and chlamydospore production in  ̂strains of £, albicans. 
Com meal agar with 1̂  Tween 80, was autoclaved at 15 psi for 15 
minutes in 500 ml screw-capped Erlenmeyer flasks. After autoclaving 
the flasks were cooled in a water bath to 50°C. After cooling, 0.6 ml 
of sterile distilled water were added to the control flask, while 0.6 
ml of amphotericin B were added to the test flask resulting in a final 
amphotericin B concentration of 2 jag/ml in a fluid volume of 3Ô0 ml. 
The media were dispensed into trisectored sterile petri plates and 
allowed to solidify. Three hours after solidification, the plates were 
inoculated in duplicate with 5 isolates of £. albicans which had been 
previously exposed to the antifungal agent. The plates were incubated 
at room temperature (2b°C) and the results recorded 7 days after inocu­
lation (Table 5). 
There was no correlation observed between prior exposure to ampho­
tericin B and the ability of the isolates to form mycelium and produce 
chlamydospores on com meal-tween agar. However, there was a constant 
significant reduction in nqrcelium formation among the strains of G. 
albicans grown on com meal-tween agar containing amphotericin B. The 
•Rie reduced mycelium formation by the strains did not appear to be 
dependent on their prior exposure to amphotericin B. 
Table 7. M'fects of previous and concurrent exposure to amphotericin B on growth and 
chlançrdospore formation by Candida albicans on com meal agar. 
IB-P 0 +++ +++ + +++ 
IB-Al 10 +++ + 
1B-A2 10 +++ + +++ 
2A-P1 0 +++ ++ +++ 
2A-P2 0 +++ +++ +++ 
2A-A1 10 ++ 
2A-A2 10 +++ +++ +++ 
2A-A3 20 + +++ 
2A-A!i 20 +++ +++ +++ 
3A-P 0 +++ +++ +f+ 
3A-A1 10 +++ +++ 
3A-A2 10 +++ 
3A-A3 10 +++ +++ 
5A-P 0 +++ •f +++ 
5A-A1 10 +++ +++ 
5A-A2 10 +++ +++ + +++ 
7A-P 0 +++ +++ +++ 
7A-A1 10 +++ 
7A-A2 20 +++ ++ 
Com meal-Ikeen 80 agar 
ial Chlangrdospore 
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*>ig amphotericin B/ml of modified Sabouraud broth, 1̂ 8 hr., 37°C. 
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Bgpertment Effect of hydrocortisone acetate on an experimentally 
Induced systemic candidosis. 
Rocky Mountain Laboratory white mice were used in this study to 
determine the effects of hydrocortisone on the course of an experiment­
ally induced systemic candidosis. The treated mice received 1.2̂  mg of 
hydrocortisone intraperitoneally daily for k days prior to being chal­
lenged with G. albicans isolate 3̂ . A saline suspaision of the chal­
lenge dose, 1 X 10̂  cells, was given intravenously in 0,1 ml. The 
composition of the various groups in this experimental study were as 
follows: 13 cortisone-treated, challenged mice; 8 challenged control 
mice; 7 cortisone-treated, unchallenged mice; and 2 saline-treated, 
control mice. "Hie results of this experiment (Figure k) clearly show 
that hydrocortisone definitely decreased the animal's ability to con­
trol the systemic candidosis. Autopsies were randomly performed to 
verify the cause of death. In some animals kidney lesions were more 
evidant than in others. 
There was one death which occurred among the hydrocortlsone-
treated, unchallenged mice. It occurred on the 11th day after hydro­
cortisone treatment was discontinued and was attributed to cannibalism. 
Earlier in the experiment two mice in the same group had incurred 
inflicted injuries to their hind quarters and were removed and isolated. 
They recovered from their wounds and survived until the termination of 
the investigation. 
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Experiment 6. Determination of the effect of immanological depression 
on the ogtcome of an amphotericin B-treated systemic candidal infection. 
Male Rffli white mice weighing from 2̂  to 30 gm were used in this 
investigation. Each group consisted of 9 mice with the exception of 
 ̂cortisone-treated control mice and 3 saline-treated control mice. 
Pretreatment of the mice with hydrocortisone acetate was carried out 
according to the procedure outlined in Experiment ?. The procedure was, 
however, modified in so far as the mice were challenged with C. albicans 
strain 3A shortly after receiving their final dose of hydrocortisone. 
The reason for this modification was to allow for the establishment of 
the systemic infection at a point of greatest immunological depression. 
Bie treated mice received 1 rag of amphotericin B 2k hours after chal­
lenge and then 0.5 mg every 1*8 hours for 6 days. On a rag/kg basis each 
mouse received approximately Î O and then 20 mg/kg, respectively» Autop­
sies were randomly performed and the kidneys examined for macroscopic 
lesions. When the cause of death was in doubt, cultures of the kidneys 
were made. Bie results of this investigation appear in Figures 5 and 6. 
Hydrocortisone was again shown in this investigation to decrease 
the ability of the infected mice to control the systemically-induced 
candidal infection. Treatment of both the cortisone- and saline-pre-
treated infected mice with amphotericin B showed that the response of 
both groups to the antibiotic was an arrest of the induced candidal 
infection. Figure 6 shows that there was approximately a h!k% fatality 
due to the doses of amphotericin B employed among the control animals 
which may account for and/or .contribute to the deaths observed in the 
infected-treated groups. 
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Figure g. Effect of amphotericin B on the course of a systeraically-induced candidal 
infection in mice pretreated with hydrocortisone acetate. Mice received the following 
injections; hydrocortisone acetate, cells, a ; saline, cells, * ; hydrocortisone acetate, 
cells, amphotericin B, m ; saline, cells, amphotericin B, it . (See text for injection 
schedule). 
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Fî re 6. Toxicity resulting from amphotericin B treatment in infected and 
uninfected mice. The mice received the following injections: hydrocortisone 
acetate, amphotericin B, o ; saline, amphotericin B, hydrocortisone acetate. 
cells, amphotericin B, saline, calls, amphotericin B, 
CHAPTER IV 
DISCUSSION 
Uie results of the to vitro broth assays of the effect of am%Aio-
terlcin B on C« albicans, showed that the 6 isolates of C. albicans were 
inhibited to different degrees by a given concentration of amphotericin 
B. Bie inhibition was partial for all isolates at 0.1 jig/nù. and com­
plete for the 6 isolates at 0.5 /ig/ml. These results are similar to 
those reported by Sorensen et al, (1959), Hald et al, (1957), and Litt-
man et al. (1958a), Their method of determining fungistasis, however, 
was based on a visual comparison of the assay tubes to determine growth 
inhibition. The use of an increase in optical density as a criterion 
for growth inhibition was considered to be a more accurate method for 
determining fungistasis than that based on visual comparison. 
There were other areas in the actual methods and materials employed 
by Littman and coworkers (1958a)and Sorensen and coworkers (1959) which 
also differed from those used in this investigation. Their use of pH 7 
and inoculum size 5 z 10̂  - 1 x 10̂  cells compared with pH 6.7 and 
inoculum size 5 x 10̂  cells/ml used in this study did not appear to 
significantly alter the fungistatic concentration of amphotericin B, 
A comparison of the pH and inoculum size used by Hald et al. (1957 ) 
can not be made since neither was reported. 
Both Littman and coworkers (1958a) and Sorensen and coworkers (1959) 
read their results after a U8-hour inoculation at 37°C. When the assay 
tubes were read earlier or later, a significantly different result was 
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reported to have occurred. Littman ê  al, (I9̂ 8a) demonstrated that ttie 
fungistatic concentration of the antibiotic varied from 0.09 p-g/ml at 
2k hours to 5.0 pg/ml at the end of 7 days. Hiis alteration in the 
fungistatic concentration of amphotericin B was attributed to its 
deterioration in the hydrated state during prolonged incubation. 
Littman*s observation may explain the low fungistatic value of 0.07 
jxg/ml reported by Utz and coworkers (19$9) for 2 strains of G, albicans 
after a 2lt-hour exposure to tdie antibiotic. 
Based upon the work of Gold et (1956), Vandeputte et al. 
(1956), Littman et al. (1958a) and Bartner et al. (1958) a 1̂ 8-hour 
incubation period was chosen for the present studies. This period 
would allow the organism sufficient time in which to grow and would 
also give a more accurate picture of the fungistatic activity of 
amphotericin B without allowing an unnecessary deterioration of the 
antibiotic. 
The assay media employed by previous investigators included Penas-
say broth with 1% glucose, asparagine broth and mycophil broth. Those 
media and that used for assays in the present investigation appeared to 
be rich enough so as not to introduce a growth limiting factor into the 
assay. However, studies employing a minimal medium (0.5# glucose, and 
0.\% peptone) which are reported here, demonstrated a significant de­
crease in growth both in the presence and in the absence of the anti­
biotic when compared to an enriched medium containing 2% glucose and \% 
peptone. The relative growth in the presence of 0.1 /ig/ml of ampho­
tericin B in the rich medium was 71.2# of the control as compared to 
55» 3# of the control in the minimal medium. Whether the greater 
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relative inhibition by the antibiotic in the low-peptone medium was a 
result of the reduced peptone concentration itself or whether there was 
a greater concentration of unbound antibiotic present in the minimal 
medium has not been shown. A reduced glucose concentration (0.$%) in 
the medium did not appear to have a significant effect on the growth 
of the organism. These observations may explain in part the low fungi­
static values (0.029-0.052 jig/ml) reported by Lones and Peacock (19̂ 9) 
who also used a medium containing 0.$# glucose and 0.1# peptone in con­
trast to the hî  inhibitory value (2.5jMî/ral) reported by Qainn et al. 
(i960) who used a very rich medium for Ç, albicans. 
An additional variable, which mast be considered in an attempt to 
contrast the results of others with those of the present study, is the 
specific isolate or "strain" of £. albicans employed in the assays. 
That strains differ in their response to a given concentration of ampho­
tericin B is demonstrated by the results of ttie present investigation 
as well as that of McNall and coworkers (19̂ 8) and Lepper and coworkers 
(1959). 
%e observation of fungicidal effects of amphotericin B on £. 
albicans in modified Sabouraud broth demonstrated qualitatively that 
cells from 5 to 6 isolates of Ç. albicans were able to survive in the 
presence of an initial concentration of $0 yig/ml of the antibiotic. 
Similar results were reported by Bald and coworkers (19̂ 7) who demon­
strated that viable cells were recoverable from 3 strains of £. albicans 
after having been exposed to 100 /ig/ml of amphotericin B for 3 days. 
The fungicidal concentration reported by Littman et al̂ . (1958a), O.lt 
)xg/ml, however, appeared to be inconsistent with their observation that 
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the minimal inhibitory concentration of amphotericin B for the same 
strain of C. albicans varied from 0.09 p-g/xal at 2k hours to $ jxg/ml at 
the end of 7 days. It must be considered that their fungicidal concen­
tration may reflect the limitations of their sampling procedure and may 
not have represented a fungicidal concentration for the entire inoculum. 
The limitations of the sampling procedure used in the present broth 
assay studies also may be considered as a factor in the failure to re­
cover viable cells from isolate 60 after it was exposed to concentrations 
greater than 10 yig/ml. However, it was possible to recover viable cells 
from the remaining 5 isolates at concentrations more than 100 times 
greater than the fungicidal concentration reported by Littman et al. 
(I9̂ 8a). 
tones and Peacock (19?9) reported a precipitation of amphotericin 
B at concentrations of 10 or 20 jig/ml of assay broth glucose and 1% 
peptone). They demonstrated that each component of the assay medium 
was capable of causing flocculation of the antibiotic in the absence of 
the other. In an attempt to eliminate the precipitate, they modified 
their medium to contain 0,S% glucose and 0.1̂  peptone. With this alter­
ation they were able to prevent precipitation of the antibiotic. When 
a similar medium was used in the present investigation, a precipitate 
was nevertheless observed at concentrations of 10 /ig/ml or more of 
amphotericin B. The precipitate was not present initially but occurred 
during incubation of both inoculated and uninoculated cultures for i|.8 
hours at 37°C. Other investigators who have employed similar media 
(Hebeka and Solotorovsky, 1965? Sorensen e;t al., 1959) have not reported 
a precipitate. Their failure to observe a precipitate may have resulted 
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from their use of shaken cultures which would tend to prevent any vis­
ible settling of the antibiotic. The use of stationary cultures by 
Lones and Peacock (19̂ 9) and in the present study was believed to be 
primarily responsible for the observation of the antibiotic precipitate» 
The precipitate could, however, be visibly eliminated by shaking the 
tubes and at no time altered the optical densities of the suspensions. 
Since amphotericin B occurs as a colloidal suspension (Bartner al., 
19̂ 8), the aggregation of micelles may not effectively reduce their 
fungistatic and/or fungicidal effects on the cell. 
Other factors may influence the fungicidal activity of amphoteri­
cin B in Sabouraud broth. Ifowever, since the same factors may also 
operate in human plasma, they will be considered with the results of 
the assays of fungicidal activity of the antibiotic in human plasma. 
The clinical significance of the recovery of viable cells from 
amphotericin B concentrations greater than 1 p.g/ml is difficult to 
ascertain since the constituents and/or their concentrations in the 
Sabouraud broth assay system are not directly comparable to those 
present in the vivo system. 
Reports of decreased growth rates, decreased ability to form 
mycelium and chlamydospores (Lones and Peacock, 19?9) and the observa­
tion of pleomorphic cells (Sorensen £b al., 19̂ 9) in amphotericin B-
resistant strains of Ç, albicans prompted a reexamination of the 
organism's ability to produce mycelia and/or chlamydospores during 
or after exposure to amphotericin B. The inoculation of com meal-
tween agar with and without 2 ̂ g/ml of amphotericin B with 5 strains 
of C. albicans and antibiotic-tolerant isolates derived from them 
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demonstrated that previous exposure to amphotericin B did not affect 
the ability of the organism to produce mycelium and chlamydospores on 
normal com meal-tween agar. Two strains did, however, show consistent 
significant differences in the amount of mycelial growth in the presence 
of 2 jag/ml of amphotericin B. Chlamydospore formation per given area 
of mycelium however appeared to be unaffected by the presence of the 
antibiotic. It appears, therefore, that exposure of C. albicans to high 
concentrations of amphotericin B does not affect the characteristics 
which are used clinically to identify £. albicans î mycelium formation, 
chlaû ydospore production and blastesis in human plasma. It is unlikely 
that £. albicans recovered from an amphotericin B-treated case would go 
unrecognized in a routine cultural examination. 
The ability of £. albicans to form hyphae (filaments or germ tubes) 
in human plasma |>r serum within 2 or 3 hours when incubated at 37°C has 
been reported by a number of investigators (Taschjian et al., I960; 
Mackenzie, D.W.R., 1962; Griffin, 196it; Dabrowa et al., 1965; Landau 
et al., 1962; Bonfante and Barroeta, 1968) and is presently felt by some 
(Taschdjian et al., I960; Bonfante and Barroeta, 1966) to be a rapid 
and reliable imthod for identifying G, albicans in the diagnostic labor­
atory. This ability was used as the criterion for determining growth 
of the organism in human plasma. 
Landau and coworkers (1956) reported that as the inoculum size 
increases the per cent blastesis or filamentation decreases. There­
fore, it is essential that the inoculum size to be used in the assay be 
carefully considered. The inoculum (5 x 10̂  cells/ml) which was em­
ployed in this study, has been reported to undergo approximately 70% 
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blastesis within 3 hours. It was therefore felt that the absence of 
blastesis for U8 hours represented a reliable indication of the fungi­
static activity of amphotericin B in plasma. In the present investiga­
tion the relative occurrence of blastesis was not precisely quantified; 
however, if it occurred in greater than about 3 percent of the cells, 
which allows for a minimal carry over of germ tubes within the inoculum, 
the result was considered positive. Otherwise, it was recorded as 
negative. 
The results of this investigation demonstrated that the fungistatic 
activity of amphotericin B when based on blastesis was higher (2.0 
pg/ml) in plasma than in Sabouraud broth (0.$ jig/ml). This difference 
in fungistatic concentrations between the plasma and the broth systems 
may in part result from the use of a more sensitive index for deter­
mining growth in plasma. However, the possibility that some plasma 
components may also influence the activity of amphotericin B can not 
be excluded (Taschdjian and Kozinn, 1961; Heite et al., 196b; Roth et 
al., 19$9; Roth and Goldstein, 1961; Louria and Brayton, 196!*; Caroline 
et al., 196U; Landau et al., 196b). 
Concurrent with the reduction in blastesis as the concentration 
of amphotericin B increased was a decrease in the length of the germ 
tube at antibiotic concentrations of 0.5 p.g/ml or more and also a de­
crease in viability within the original inoculum. 
Other investigators (Vogel and Crutcher, 1958; Littman et al., 
1958b; McNall et al., 1958; Gerke and Madigan, 1961) have studied the 
fungistatic effects of amphotericin B on Ç. albicans and on other Can­
dida species in serum and other body fluids. However, with one 
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exception, their results are not directly comparable with the present 
study since the criteria for growth, the assay medium diluent and other 
materials and procedures were significantly different such as to render 
the validity of a comparison questionable. 
The only report found in the literature which included blastesis 
as an indicator of the effect of amphotericin B on albicans was that 
by Landau and coworkers (1965) who used a serum assay medium. They 
reported that blastesis in sera incubated for 3 hours was less than 
when the amphotericin B concentration was 5 jag/ral or more, and \S% 
at a concentration of 1 ;ig/ml, as compared to the control with 8$#. 
The variation which they observed in the percentage of germination in 
duplicate tests did not exceed 10̂  and an average was reported as the 
result. 
The results reported by Landau and coworkers (196$) were determined 
after 3 hours at 37°C. A 3-hour incubation period, although it is 
sufficient time to demonstrate blastesis in the diagnostic laboratory, 
was not considered to be a realistic time from a clinical point of 
view to determine the activity of the antibiotic. In most clinical 
cases, U8 hours represents the maximum time which would elapse between 
infusions of the antibiotic. It was therefore decided that it would 
be of more value to measure the activity of a given conaentration of 
amphotericin B at this clinical limit than at a time which may not be 
long enough to represent an accurate indication of its possible ̂  vivo 
effectiveness. Secondarily, a U8-hour incubation period was considered 
since it would allow comparison of results with those obtained using 
the Sabouraud broth assay system. 
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The fungicidal activity of amphotericin B in human plasma was 
demonstrated in the present investigation to be greater than in Sabou-
raud broth. Viable cells were not recovered after exposure to greater 
than 3 }ig/ml of amphotericin B when subcultured on blood agar. How­
ever, evidence of viability could still be demonstrated if the assay 
sample was diluted with sufficient trypticase soy broth to reduce the 
concentration of amphotericin B below the fungistatic level. At an 
amphotericin B concentration of 5 ̂g/ml even after dilution, viability 
was lost in ̂ 0% of the samples from 3 of the it isolates of C. albicans 
tested. 
In the bioassay studies previously mentioned, the fungicidal 
effects of amphotericin B on C. albicans in human plasma or serum were 
not investigated. 
In 1963, Louria and Brayton reported the presence of a candida-
cidal substance in human plasma and serum. The substance was reported 
(Louria and Brayton, 196̂ ) to remain active 2 weeks when refrigerated 
at li°C and indefinitely when frozen at -20°C. It was therefore not 
considered to influence the results of the present investigation. 
Other factors which may have influenced the fungistatic and/or fungi­
cidal activity of amphotericin B in plasma includes the isolate of G. 
albicans employed, the size of the inoculum, the growth phase of the 
inoculum (McNall et al., 1958), the duration of antibiotic contact 
with the organism, and in the case of plasma, the medium itself may 
contribute to the fungicidal activity observed. 
The results presented here have shown that C. albicans is able 
to grow in the presence of an amphotericin B concentration (1,0 /ig/ml) 
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which approximates the highest in vivo concentration which can safely 
be maintained for about 2k hours. However, there was a marked reduction 
in viability accompanying the limited growth at 1 /ig/ml and, as demon­
strated by failure to obtain subcultures on blood agar, viability was 
lost at an antibiotic concentration of jag/ml. Since the effects re­
ported here represent a single contact with the antibiotic and not a 
repeated contact as would occur in a clinical infection, the growth and 
viability demonstrated in this study although they are of academic sig­
nificance may not be of clinical significance. 
]h conclusion, the plasma assay system aftpeared to demonstrate a 
greater fungicidal activity of amphotericin B than did the Sabouraud 
broth system. Although there was apparent growth (blastesis) of G, 
albicans in plasma at an amphotericin B concentration of 1 pg/ml, the 
growth was not sufficient enough to impart visible turbidity to the 
plasma tubes containing 0.̂  pg/ml of amphotericin B when visually com­
pared to the control. It was therefore considered that the fungistatic 
activity of amphotericin B in both assay systems was similar. 
The effects of amphotericin B on growth of the mycelial phase of 
G. albicans in Sabouraud broth or human plasma were not considered in 
this investigation. 
The steroid hormones ACTH, cortisone, and hydrocortisone have been 
shown by a number of investigators to depress host resistance to mycotic, 
bacterial and viral infections (Seligmann, 19̂ 3; Louria e;b , I960; 
Hellman, A., 1965; Foley et al., 1957; Batten and McCune, 1957). The 
mechanisms by which they lower host resistance include? a decrease in 
the inflammatory response process (Ketchel et al., 1958; Menkin, 7., 
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19̂ h? Michael and Whorton, 19̂ 1), decreased antibody production 
(Bĵ meboe ejb aT̂ ., 19̂ 1; Kass et al., 1955; Siedlicka et , 1963; 
Germath and Ottinger, 1950), lymphopenia (Paluska and Hamilton, 1963) 
. . . and a decreased phagocytic activity (Crepea et al., 1951). 
In 1961, Boyd and Chappell reported a systemic Ç, albicans infec­
tion which terminated fatally after combined steroid and antibiotic 
therapy. The present study was undertaken to determine if the iraraono-
logical depressant effects produced by the steroid hormone, hydrocor­
tisone, could be over come by the administration of amphotericin B. 
To determine this, the effect of hydrocortisone acetate on the course 
of an induced systemic candidal infection was first investigated. 
!Itie results of this investigation showed that a significant in­
crease in mortality rate occurred when mice were pretreated with 
hydrocortisone as compared to the control group. In Experiment 5 
there was a 0̂% mortality in the hydrocortisone pretreated group on 
the sixth postinfectional day as compared to 12.5% in the control 
group. In a second experiment (Experiment 6), on the sixth post­
infectional day there was a 77% mortality in the hydrocortisone pre­
treated group as compared to 22% in the control group. These studies 
very clearly demonstrate the adverse effects exerted by hydrocortisone 
on the course of systemic candidal infections. 
Hrairy and Fahlberg in I960 reported that hydrocortisone acetate 
(l to 10 mg) given as a single intraperitoneal injection 2li hours 
prior to challenge with Ç. albicans by the same route did not produce 
an increase in the mortality rate. However, repeated daily doses of 
hydrocortisone acetate given intraperitoneally over a 2-week period 
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brought about an enhancement of the candidal infection and correlated 
directly with the amount of hydrocortisone acetate given. When 1.0 mg 
of hydrocortisone acetate was given daily for 2 weeks, the mortality 
rate in the hydrocortisone-treated group was as compared to 13% for 
the control group. Di the present study, 1.2$ mg of hydrocortisone 
acetate given for L. successive days before challenge with £. albicans 
was shown to produce a similar enhancement of the candidal infection 
and increase in the mortality rate. 
Using the immunological depressant effects of hydrocortisone ace­
tate to establish a rapidly fatal systemic candidal infection, the 
effect of amphotericin B on the course of this infection was investi­
gated. Hie results at the termination of the experiment showed that 
amphotericin B in the dose regimen employed was able to arrest the 
systemic infection in both amphotericin B-treated groups. In the l8th 
postinfectional day, there was 100$ mortality in both the hydrocortisone-
and saline-treated infected groups as compared to a mortality and a 
55$ mortality in the hydrocortisone and control groups receiving ampho­
tericin B. In this study the effects of temporary immunological depres­
sion were overcome and the systemic candidal infection was arrested by 
the use of amphotericin B. 
The dose of amphotericin B used in the present investigation may 
have accounted for the deaths observed in both infected-treated groups 
as is evidenced by the kk$ mortality in both antibiotic control groups 
(Figure 6). The uncomplexed form of amphotericin B when given intra-
peritoneally in concentrations from ̂  to 100 mg/kg was reported by 
Sternberg and coworkers (1956) not to produce chronic toxicity. Emmons 
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and Piggott (1959) did not report any fatal toxicity resulting from the 
administration of $6 mg/kg of crystalline amphotericin B to mice intra-
peritoneally. However, they did report that the same solubilized form 
of the antibiotic as was used in the present study when given intra­
venously produced fatal toxic effects in the control mice at a concen­
tration of 2.2 mg/kg. In the present investigation the intraperitoneal 
route was used in an attempt to increase the concentration of amphoter­
icin B which could be given and decrease its toxic effects. Although 
the intraperitoneal route was shown to increase the tolerable concen­
tration of antibiotic, amphotericin B in the concentrations given still 
produced serious toxic side effects. 
At the termination of this experiment, autopsies performed on the 
surviving normal and immune—suppressed amphotericin B-treated infected 
mice—revealed macroscopic cortical kidney lesions and yeast-like cells 
in a number of renal tubules. These observations together with the 
death which occurred in an amphotericin B-treated mouse on the 12th 
postinfectional day suggest that amphotericin B even in the high concen­
trations (almost an given to animals with normal host defense 
mechanisms was not adequate to eliminate the infecting organism from 
the host. 
Since albicans is capable of invading and residing within the 
kidney of mice, it would appear to be capable of producing an acute 
infection in the untreated animal and a chronic infection in the treated 
animal. Farther research, however, is required to demonstrate this 
chronic state. 
Ui 
%e significance of this investigation is that amphotericin B was 
shown to be able to compensate when given early in the course of a 
systemic candidal Infection for a temporary impaimnent of the defense 
mechanisms of the afflicted host. In a clinical systemic candidal in­
fection, an impairment of the host's defense mechanisms may also be 
temporarily compensated for by the early administration of amphotericin 
B; however, ultimately amphotericin B may be dependent to some degree 
on the host's defense mechanisms, in particular the host's cellular 
defense mechanisms, to complete its antimicrobial effect. 
CHAPTER 71 
SUMMART 
Six isolates obtained from clinical infections were characterized 
and identified as C. albicans. 
A fungistatic concentration of amphotericin B was determined for 
each of the 6 isolates of C. albicans in Sabouraud broth. The 
fungistatic concentrations of amphotericin B ranged from 0,1̂  jug/ml 
to 0.5 pg/ml. 
A fungicidal concentration of amphotericin B (10 pg/ml) was 
demonstrated for only 1 (isolate 60) of the 6 isolates of C. 
albicans in Sabouraud broth. Viable cells were recovered from 
the remaining 5 isolates at amphotericin B concentrations as high 
as 50 pg/ml. 
The ability of $ isolates of G, albicans to produce mycelium and 
ohlamydospores after exposure to 10 or 20 jug/ml of amphotericin B 
was unaltered. However, mycelium formation (but not chlamydospore 
production) was reduced in 2 isolates of C, albicans (IB and $k) 
when grown on com meal-tween agar in the presence of 2 ;ig/ml of 
amphotericin B. 
The growth of 0. albicans as well as the inhibitory activity of 
amphotericin B were shown to be Influenced by the concentration of 
peptone In the assay medium. In a low peptone medium (0.1%) the 
growth of 2' albicans was significantly reduced and the Imhibitory 
activity of amphotaricln B increased as compared to an assay medium 
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with a high peptone concentration (l.O/K), 
6. %e concentrations of glucose used in the assay media did not 
appear significantly to affect the growth of Ç. albicans, or the 
inhibitory activity of amphotericin B, 
7. Using blastesis as a criterion for determining fongistatis, the 
fungistatic concentration of amphotericin B was shown to be greater 
in plasma (2,0 jag/ml) than in Sabouraud broth (O.lt-0,̂  jig/ml) for 
ij. isolates of £, albicans. 
8. A fungicidal concentration of amphotericin B in plasma as measured 
by the recovery of viable cells on blood agar plates was demon­
strated for k isolates of £. albicans to be U jig/ml. 
9. £. albicans, isolate 3A, was shown to be pathogenic for male white 
mice. 
10, Hydrocortisone acetate was shown to increase significantly the 
mortality rate of mice infected with £, albicans. 
11, Bie immunological depressant effects of hydrocortisone treatment 
of infected mice were overcome and the systemic candidal infection 
arrested by the use of amphotericin B. 
12, There was some evidence to suggest that the concentrations of 
amphotericin B used to treat the systemic candidal infection, 
although toxic to some of the mice, were unable even in normal 
hosts to rid the animal of the infecting organism. 
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